[go: up one dir, main page]

WO2018174294A1 - Régulateur de nerf autonome, composition alimentaire pour la régulation du nerf autonome et technologie associée - Google Patents

Régulateur de nerf autonome, composition alimentaire pour la régulation du nerf autonome et technologie associée Download PDF

Info

Publication number
WO2018174294A1
WO2018174294A1 PCT/JP2018/011941 JP2018011941W WO2018174294A1 WO 2018174294 A1 WO2018174294 A1 WO 2018174294A1 JP 2018011941 W JP2018011941 W JP 2018011941W WO 2018174294 A1 WO2018174294 A1 WO 2018174294A1
Authority
WO
WIPO (PCT)
Prior art keywords
autonomic nerve
autonomic
psychological stress
stress environment
nerve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2018/011941
Other languages
English (en)
Japanese (ja)
Inventor
隆彦 藤川
英夫 竹腰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SUN CHLORELLA CORP
Original Assignee
SUN CHLORELLA CORP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SUN CHLORELLA CORP filed Critical SUN CHLORELLA CORP
Priority to JP2019507051A priority Critical patent/JPWO2018174294A1/ja
Publication of WO2018174294A1 publication Critical patent/WO2018174294A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Definitions

  • the present invention relates to an autonomic nerve regulator, a food composition for autonomic nerve regulation, and related techniques.
  • Japanese Patent Application Laid-Open No. 2007-8878 discloses a therapeutic agent for non-motility and non-acute stress fatigue comprising eleuteroside B or eleuteroside E in an extract of Ezokogi as an active ingredient.
  • a drug containing an extract of Ezokogi as an active ingredient a drug effective for the treatment or prevention of stress gastric ulcer through the elevation effect of in vivo prolactin, the treatment or prevention of stress acute enterocolitis Effective drugs, drugs effective for the treatment or prevention of stress insomnia, drugs effective for the treatment or prevention of stress irritability, and the like.
  • JP 2017-7974 discloses a cardiac function regulator that uses an extract of hot water of root of elephant root as an active ingredient to regulate autonomic nervous function in response to various environmental changes.
  • the present invention relates to an autonomic nerve modulator, an autonomic nerve regulator food composition, and an autonomic nerve regulator that exerts an effect of regulating autonomic nerves, particularly an effect of regulating autonomic nerve functions in response to environmental changes to a psychological stress environment It is an object of the present invention to provide a method for controlling autonomic nerves as well as the use of eleuteroside E for the production of
  • the autonomic nerve modulating agent and autonomic nerve modulating food composition of the present invention can be expressed as follows, for example.
  • An autonomic nervous regulator comprising eleuteroside E as an active ingredient.
  • the above autonomic nerve modulator is for suppressing the increase of sympathetic nerve function and the decrease of parasympathetic nerve function in the environmental change to the psychological stress environment (2-2) Use of description.
  • the autonomic nerve regulator and food composition for autonomic nerve regulation of the present invention have an effect of regulating autonomic nerves, particularly an effect of regulating autonomic nerve functions in response to environmental changes to a psychological stress environment.
  • Eleuteroside E which is an active ingredient of the autonomic nerve regulator and food composition for autonomic nerve regulation of the present invention, is represented by the following structural formula.
  • Eleutheroside E can be obtained, for example, from Ezoukogi (Scientific name: Acanthopanax senticosus Harms), which is a plant belonging to the family Argiaceae, by the method described in JP 2007-8878 A (Japan). Can do.
  • the autonomic nerve modulating agent of the present invention can be applied to those who need autonomic nerve control, for example, by oral administration, but the administration method is not necessarily limited to oral administration.
  • the adjustment of the autonomic nerve function the adjustment corresponding to the environmental change to the psychological stress environment, the adjustment to suppress the increase of the sympathetic nerve function and the decrease of the parasympathetic nerve function in the environmental change to the psychological stress environment. Examples include adjustment when the psychological stress environment is a psychological stress environment due to fear or anxiety, adjustment when the psychological stress environment due to fear or anxiety is an altitude environment, and the like.
  • the form of oral administration of the self-sustaining neuromodulator of the present invention is not particularly limited, and for example, it can be a powder, a tablet, a hard capsule, a soft capsule, a solution dissolved in water, or other solution.
  • various excipients in forming various forms, various excipients, binders, disintegrants, lubricants, coating agents, coloring agents, flavoring agents, flavoring agents, plasticizers, and the like can be used as appropriate.
  • excipients examples include sugars (lactose, sucrose, glucose, mannitol), starch (potato, wheat, corn), minerals (calcium carbonate, calcium sulfate, sodium bicarbonate, sodium chloride), crystalline cellulose, plant powder ( Licorice powder, gentian powder) and the like.
  • binders examples include starch paste, gum arabic, gelatin, sodium alginate, meth / recellulose (MC), ethylcellulose (EC), polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), hydroxypropylcellulose (HPC). , Carboxymethylcellulose (CMC) and the like.
  • disintegrants examples include starch, agar, gelatin powder, crystalline cellulose, CMC / Na, CMC / Ca, calcium carbonate, sodium bicarbonate, sodium alginate and the like.
  • lubricants examples include magnesium stearate, talc, hydrogenated vegetable oil, macrogol, silicone oil and the like.
  • coating agents include sugar coating (sucrose, HPC, shellac), glue (gelatin, glycerin, sorbitol), film coating [hydroxypropyl methylcellulose (HPMC), EC, HPC, PVP], enteric coating [hydroxyprovir Methyl cellulose phthalate (HPMCP), cellulose acetate phthalate (CAP)] and the like.
  • colorants include water-soluble food dyes and lake dyes.
  • examples of the corrigent include lactose, sucrose, glucose, mannitol) and the like.
  • flavoring agents include aromatic essential oils) and light blocking agents (titanium oxide).
  • examples of the plasticizer include phthalic acid esters, vegetable oils, polyethylene glycol) and the like.
  • the human oral intake requiring the autonomic nerve regulation of the autonomic nerve modulating agent and the food composition for autonomic nerve regulation of the present invention is, for example, 5 mg / day or more in the content of eleuteroside E as an active ingredient. preferable.
  • a 6-week-old SD male rat is preliminarily raised for 1 week, and then a biopotential transmitter (Bioresearch transmitter TR50, Smartpad TR180, PowerLab16 / 35 PL3516) is attached to each rat to examine autonomic function without anesthesia.
  • the control group (CONT) and the eleuteroside E group (SYG) were divided.
  • the eleutocide E group and the control group were allowed to freely ingest MF feed (Oriental Yeast Co., Ltd.), and the eleutocide E group had 8 mg / mL of eleuteroside E (SYG). 1 mL of an aqueous solution and 1 mL of distilled water were orally administered to the control group once a day.
  • the rat was placed on an elevated (180 cm height) open arm (elevated environment, i.e. fear or anxiety) before the final oral administration of the aqueous solution and distilled water (0 minutes) and 30 minutes after the administration.
  • Elevated environment i.e. fear or anxiety
  • LF / HF ratio balance between sympathetic nerve activity and parasympathetic nerve activity
  • LFnu normalized indicator of sympathetic activity
  • HFnu normalized parasympathetic (vagus) nerve activity index
  • FIG. 1 LF / HF ratio
  • FIG. 2 LFnu
  • FIG. 3 HFnu
  • Eleutheroside E suppresses the increase of sympathetic nerve function under high-temperature stress environment and suppresses the decrease of parasympathetic nerve function.

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne : un régulateur de nerf autonome et une composition alimentaire pour la régulation du nerf autonome présentant un effet de régulation des nerfs autonomes, en particulier l'effet de régulation de la fonctionnalité nerveuse autonome en réponse à des changements environnementaux dans l'environnement de stress psychologique ; l'utilisation d'éleuthéroside E pour produire un régulateur de nerf autonome ; et un procédé de régulation de nerf autonome. La présente invention concerne un régulateur de nerf autonome ayant comme principe actif l'éleuthéroside E, qui régule la fonction nerveuse autonome en réponse à des changements environnementaux dans l'environnement de stress psychologique ; et une composition alimentaire pour la régulation du nerf autonome contenant en tant que principe actif l'éleuthéroside E. L'accélération de la fonction nerveuse sympathique est supprimée et le déclin de la fonction nerveuse parasympathique est supprimé dans des changements environnementaux de l'environnement de stress psychologique.
PCT/JP2018/011941 2017-03-24 2018-03-23 Régulateur de nerf autonome, composition alimentaire pour la régulation du nerf autonome et technologie associée Ceased WO2018174294A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019507051A JPWO2018174294A1 (ja) 2017-03-24 2018-03-23 自律神経調節剤及び自律神経調節用食品組成物並びにその関連技術

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017-060225 2017-03-24
JP2017060225 2017-03-24

Publications (1)

Publication Number Publication Date
WO2018174294A1 true WO2018174294A1 (fr) 2018-09-27

Family

ID=63584619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/011941 Ceased WO2018174294A1 (fr) 2017-03-24 2018-03-23 Régulateur de nerf autonome, composition alimentaire pour la régulation du nerf autonome et technologie associée

Country Status (3)

Country Link
JP (1) JPWO2018174294A1 (fr)
TW (1) TW201842926A (fr)
WO (1) WO2018174294A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12409202B2 (en) 2021-07-30 2025-09-09 Fujicco Co., Ltd. Autonomic nerve regulator and cognitive function improver

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007008878A (ja) * 2005-06-30 2007-01-18 Sato Pharmaceutical Co Ltd 非運動性及び非急性ストレス性疲労の治療剤
WO2014084460A1 (fr) * 2012-11-30 2014-06-05 씨제이제일제당 (주) Composition comprenant un extrait d'acanthopanax koreanum en tant que principe actif pour prévenir ou traiter les troubles neuropsychiatriques
CN104490904A (zh) * 2014-12-17 2015-04-08 黑龙江金九药业股份有限公司 一种治疗神经衰弱的药物组合物及其制备方法
JP2017007974A (ja) * 2015-06-19 2017-01-12 株式会社サン・クロレラ 心機能調節剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007008878A (ja) * 2005-06-30 2007-01-18 Sato Pharmaceutical Co Ltd 非運動性及び非急性ストレス性疲労の治療剤
WO2014084460A1 (fr) * 2012-11-30 2014-06-05 씨제이제일제당 (주) Composition comprenant un extrait d'acanthopanax koreanum en tant que principe actif pour prévenir ou traiter les troubles neuropsychiatriques
CN104490904A (zh) * 2014-12-17 2015-04-08 黑龙江金九药业股份有限公司 一种治疗神经衰弱的药物组合物及其制备方法
JP2017007974A (ja) * 2015-06-19 2017-01-12 株式会社サン・クロレラ 心機能調節剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
1 February 2016 (2016-02-01), Retrieved from the Internet <URL:http:nenkai.pharm.or.jp/136png/28AB-pml51.png> [retrieved on 20180604] *
1 February 2017 (2017-02-01), Retrieved from the Internet <URL:http:nenkai.pharm.or.jp/137png/26PA-am064.png> [retrieved on 20180604] *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12409202B2 (en) 2021-07-30 2025-09-09 Fujicco Co., Ltd. Autonomic nerve regulator and cognitive function improver

Also Published As

Publication number Publication date
JPWO2018174294A1 (ja) 2020-01-23
TW201842926A (zh) 2018-12-16

Similar Documents

Publication Publication Date Title
CN106236739B (zh) 含有叶黄素/叶黄素酯的组合物及其应用
US20190192466A1 (en) Method of using omega 3 fatty acids to treat diseases which involve damage to the nervous system
EP2249823A2 (fr) Formulation d&#39;acide octanoïque et procédés de traitement les employant
JP2017007974A (ja) 心機能調節剤
WO2018174294A1 (fr) Régulateur de nerf autonome, composition alimentaire pour la régulation du nerf autonome et technologie associée
JP2009051765A (ja) 男性機能増強剤
JP2020526485A5 (fr)
US4020159A (en) Methods of and medications for treating cardiac disorders by using strophanthin
CN104147380B (zh) 一种具有缓解视疲劳作用的药物组合物、制备方法及应用
US20180289708A1 (en) Low dose oral dipyridamole compositions and uses thereof
CN103638362A (zh) 一种治疗小儿鹅口疮的口腔凝乳剂
JP5877773B2 (ja) 交感神経抑制剤
Chin et al. Rapid initiation, titration, and transition from IV to oral treprostinil: A retrospective study
CN107158347A (zh) 一种治疗心脏疾病的药物组合物及制备方法和用途
CN107529440B (zh) 一种治疗雷诺病的组合物及其制备方法
JP6890810B2 (ja) ＢＤＮＦ−ＴｒｋＢシグナル伝達系活性化剤及びＢＤＮＦ−ＴｒｋＢシグナル伝達系活性化用食品組成物
JP2019156721A (ja) 血流改善用可食組成物
JP7127782B2 (ja) 学習効果改善剤及び学習効果改善用食品組成物の製法並びにその関連技術
US2465233A (en) Motion sickness chewing gum
WO2018181136A1 (fr) Procédé de production d&#39;un médicament anxiolytique et composition de produit alimentaire anxiolytique et technologie associée
CN108478567A (zh) 药物新剂型
US10953025B2 (en) Composition, device and method for delayed and sustained release of brain energy molecules
CN106620253A (zh) 一种治疗缓慢性心律失常的中药组合物
KR20150123302A (ko) 특정한 체외 용해 프로파일 또는 약리역학 파라미터를 갖는 도네페질의 약제학적 조성물
CN104784185B (zh) 奈韦拉平药物组合物及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18772257

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019507051

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18772257

Country of ref document: EP

Kind code of ref document: A1